Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients

Endocrine Journal

Volumn 60, Issue 7, 2013, Pages 871-876

  Tsushima, Yukiko ^a,b   Miyauchi, Akira ^b   Ito, Yasuhiro ^b   Kudo, Takumi ^b   Masuoka, Hiroo ^b   Yabuta, Tomonori ^b   Fukushima, Mitsuhiro ^b   Kihara, Minoru ^b   Higashiyama, Takuya ^b   Takamura, Yuuki ^b   Kobayashi, Kaoru ^b   Miya, Akihiro ^b   Kikumori, Toyone ^a   Imai, Tsuneo ^a   Kiuchi, Tetsuya ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b KUMA HOSPITAL   (Japan)

Author keywords

Papillary thyroid carcinoma; Prognostic factor; Thyroglobulin antibody

Indexed keywords

THYROGLOBULIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CARCINOMA; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880930849     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0410     Document Type: Article

References (16)

1. Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, et al. (2011) Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21: 707-716.
2. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS (2005) Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 90: 5566-5575.
3. Spencer CA (2011) Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 96: 3615-3627.
4. Chung JK, Park YJ, Kim TY, So Y, Kim SK, et al. (2002) Clinical significance of elevated level of serum antithyroglobulin antibody in patients withdifferentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 57: 215-221.
5. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, et al. (2008) Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 93: 4683-4689.
6. Sobin LH, Gospodarowicz MK, Wittekind C (2010) International Union against Cancer. TNM classification of malignant tumours (7th). Wiley-Blackwell, New York.
7. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, et al. (2003) Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139: 346-351.
8. Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, et al. (2005) Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 153: 49-55.
9. Takamura Y, Nakano K, Uruno T, Ito Y, Miya A, et al. (2003) Changes in serum TSH receptor antibody (TRAb) values in patients with Graves' disease after total or subtotal thyroidectomy. Endocr J 50: 595-601.
10. Tomoda C, Miyauchi A (2012) Undetectable serum thyroglobulin levels in patients with medullary thyroid carcinoma after total thyroidectomy without radioiodine ablation. Thyroid 22: 680-682.
11. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD (2010) The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 20: 1235-1245.
12. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, et al. (2012) Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab 97: 1526-1535.
13. Tuttle RM, Leboeuf R, Shaha AR (2008) Follow up approaches in thyroidcancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37: 419-435.
14. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, et al. (2010) Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20: 1341-1349.
15. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, et al. (2011) Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165: 441-446.
16. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19: 1167-1214.